Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin in combination with insulin for type 2 diabetes
NCT00099931Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin + Insulin with Placebo + Insulin (2 arms). Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started May 2004; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00099931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099931.